Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2026-02-06 00:00:00 ET · period of report 2026-02-05 · accession 0001683168-26-000803 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-06 | 2026-02-05 | PHIO | Bitterman Robert J | COB, Pres, CEO, Dir | A - Grant | $0.00 | +120.0K | 411.4K | +41% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $.0001 par value | 2026-02-05 | A | A | 120,000 | $0.00 | 411,421 | D | — | — | (F1) Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant. (F2) Includes shares of common stock underlying unvested restricted stock units. |